| Document |
Document Title |
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/153775A1 |
The present invention relates to compounds of formula (I), (I) or pharmaceutically acceptable salts and/or solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined in the claims, which are useful as inhibitors of...
|
|
WO/2024/153208A1 |
Compounds represented by formula (I) or stereoisomers thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof, each group in the formula being defined in the description, a pharmaceutical composition comprising the co...
|
|
WO/2024/149819A1 |
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
|
WO/2024/148049A1 |
The present invention provides compounds, compositions thereof, and methods of using the same to treat IRAK4-mediated disorder, disease, or condition in a patient.
|
|
WO/2024/147703A1 |
Provided are an SHP2 inhibitor, a pharmaceutical composition comprising same for preventing or treating SHP2-related diseases, a method for treating and preventing diseases using the composition, and uses thereof. According to the presen...
|
|
WO/2024/146608A1 |
An electron transport material, a preparation method, and a perovskite solar cell device. The electron transport material is of a fused ring structure formed by using indole as a framework and bridging a benzodiazole compound. According ...
|
|
WO/2024/140431A1 |
Among other things, the present disclosure provides compounds of formula I or salts thereof. In some embodiments, provided compounds are useful as TRPV3 inhibitors. In some embodiments, the present disclosure provides methods for prevent...
|
|
WO/2024/140294A1 |
The present invention belongs to the technical field of organic light-emitting devices (OLEDs). Particularly disclosed is an organic compound represented by formula (I), and also disclosed is an application of the organic compound in an ...
|
|
WO/2024/140970A1 |
Disclosed in the present invention are a bicyclic compound and a use thereof in drugs, particularly relating to a novel bicyclic compound and a pharmaceutical composition containing the compound. The invention also relates to a preparati...
|
|
WO/2024/131772A1 |
The present application relates to a compound having a STING inhibitory effect and a pharmaceutical composition thereof, and use thereof in the preparation of a medicament for preventing and/or treating diseases related to abnormal STING...
|
|
WO/2024/133292A1 |
The invention relates to novel CCR8 antagonists, based on NS-15 as lead structure, were designed and synthesized. To maintain the hydrogen bond potential, focus was on the isosteric replacements of the amide bond. In addition, isosters o...
|
|
WO/2024/133014A1 |
The present disclosure provides certain phenylpiperidine derivatives of formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferas...
|
|
WO/2024/126773A1 |
A compound with the Formula (I): A-B-C wherein A is of the following formula (AA) and X1 is selected from O, S or NH; X2 is either N or C-H; X3 is either N or C-RA3; wherein if X1 is NH and X2 is C-H then X3 is C-RA3; B is of formula (B-...
|
|
WO/2024/128163A1 |
The compound represented by the following formula has excellent lasing properties. G1 and G2 represent H or a substituent; SP1 and SP2 represent benzofurylene, dibenzofurylene, etc., and Q1 and Q2 represent H, alkyl, alkoxy or a halogen,...
|
|
WO/2024/128788A1 |
The objective of the present invention is to provide a compound having a novel structure, and a preparation method therefor, the compound being effectively usable as an electron acceptor material of an organic solar cell. Particularly, t...
|
|
WO/2024/120275A1 |
The present invention provides a preparation method for Edoxaban or a salt or hydrate thereof. The method comprises the following steps: step 1: under acidic conditions and in a polar solvent, removing the N-Boc protecting group of chemi...
|
|
WO/2024/121261A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2024/122617A1 |
The present invention provides a compound having an antagonist and/or inverse agonist action on the serotonin 5-HT2A receptor as well as an antagonist and/or inverse agonist action on the serotonin 5-HT2C receptor, or a pharmaceutically ...
|
|
WO/2024/115338A1 |
A compound of formula (I): [(Fu)r-L]s-(NFA)t, Fu is a fullerene; NFA is a non-fullerene acceptor; L is a linker group; r, s and t are each at least 1; and NFA is a non-fullerene acceptor. The NFA contains electron-accepting groups, elect...
|
|
WO/2024/118858A1 |
Provided are compounds of Formula I, Formula Ia and Formula Ib and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ia an...
|
|
WO/2024/115733A1 |
The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, (I) wherein A, R...
|
|
WO/2024/114639A1 |
The application relates to a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which degrades HuR, a pharmaceutical composition comprising a compound of Formula (...
|
|
WO/2024/112611A1 |
Provided are compounds that may bind a target protein, and result in modification of the target protein. The compounds may further bind a modifier protein. The modifier protein may carry out or enhance the modification of the target prot...
|
|
WO/2024/108670A1 |
Disclosed are an edoxaban key intermediate and a synthesis method therefor. The edoxaban key intermediate is shown as (1) and is prepared by means of an ammonolysis reaction of raw materials. The intermediate can be used for preparing ed...
|
|
WO/2024/107778A1 |
Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are useful for treating coronavirus infection via inhibition of the protease Mpro.
|
|
WO/2024/105364A1 |
The present invention relates to compounds of formula (I). The compounds may be used to inhibit Cdc-Like Kinases, and thereby treat cancer, inflammatory disease, neurodegenerative disease, infection, tendinopathy, Duchenne muscular dystr...
|
|
WO/2024/103123A1 |
Described herein are improved methods of making Compound 1 (4S,7S,10aS)-4-((S)-2- mercapto-3-phenylpropanamido)-5-oxooctahydro-7H-pyrido[2,1-b
][1,3]thiazepine-7-carboxylic acid, or Omapatrilat, and purified Omapatrilat obtained from the...
|
|
WO/2024/098273A1 |
An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...
|
|
WO/2024/098735A1 |
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...
|
|
WO/2024/099438A1 |
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...
|
|
WO/2024/099386A1 |
The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutically acceptable salt the...
|
|
WO/2024/099898A1 |
The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...
|
|
WO/2024/099478A1 |
A selective inhibitor of PI3Kδ, and a free base, isomer, solvate, pharmaceutically acceptable salt and other structural forms thereof. The compounds have significant antagonistic activity on PI3Kδ, and a pharmacokinetic study shows tha...
|
|
WO/2024/097296A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/088189A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
|
|
WO/2024/088407A1 |
Disclosed are a nitrogen-containing fused ring compound as shown in formula (I), an intermediate thereof, a preparation method therefor and the use thereof. The compound has a DNA polymerase θ inhibitory activity, and can be used for tr...
|
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
|
WO/2024/046471A9 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/082959A1 |
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. This fluorescent compound is then encapsulated by polymer matrix to yield nanoaggregates which is confirmed to show an ...
|
|
WO/2024/083980A1 |
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2024/086252A1 |
The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...
|
|
WO/2024/086634A1 |
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
|
|
WO/2024/083223A1 |
The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
|
|
WO/2024/082958A1 |
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. The present invention also shows application for imaging-guided phototheranostic with the integration of both photodyna...
|
|
WO/2024/077391A1 |
Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are o...
|
|
WO/2024/076300A1 |
Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/073658A1 |
The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...
|
